Meeting
2022 ASCO Annual Meeting
A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC).
Authors
Nusayba Ali Bagegni
Washington University in St. Louis School of Medicine, St. Louis, MO
Nusayba Ali Bagegni , Leslie Nehring , Jill Anderson , Brittney Haas , Jingqin Luo , Meghna S. Trivedi , Laura Carpin Kennedy , Manali A. Bhave , Karen Colleen Daily , Wajeeha Razaq , Yiling Lu , Wei-Lien Wang , Gerburg M. Wulf , Rabih Said , Cynthia X. Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT04345913
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS1128)
DOI
10.1200/JCO.2022.40.16_suppl.TPS1128
Abstract #
TPS1128
Poster Bd #
494b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1 study of OBT076, a first-in-class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy, and PK/PD results.
First Author: Olivier Rixe
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer.
First Author: Saranya Chumsri
Poster
2013 ASCO Annual Meeting
The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple-negative breast cancer (TNBC).
First Author: Ahmad Awada